News
Perceptions of the value of generics in Brazil
2017-03-13 Generics were first approved in Brazil in 1999. Substitution of generics and reference drugs can occur at the time of purchase and upon patients’ request,… Read More »
Clinical and regulatory issues for biosimilars
2017-03-10 As the first biosimilars are being approved in the US, there are a number of clinical and regulatory issues that must be considered for the… Read More »
Perceptions of the effectiveness and quality of generics
2017-03-08 More than a quarter of doctors and the general public believe that generics are less effective and of poorer quality than brand-name drugs, according to… Read More »
A strategic approach to increase uptake of biosimilars in Spain
2017-03-06 Ainhoa Aranguren Oyarzábal and colleagues from the Madrid Health Service (MHS), Spain, describe the strategic approach that has been introduced in Spain to try and… Read More »
Generics perceptions in patients, pharmacists and doctors
2017-03-03 A significant proportion of the general public, pharmacists and doctors have negative perceptions about generics, according to a study carried out by researchers from New… Read More »
Switching between originator and follow-on iron-sucrose
2017-03-01 Researchers from France describe and compare the haematological parameters and anaemia medications used in chronic kidney disease (CKD) patients undergoing haemodialysis, before and after switching… Read More »
Substitution of generic antiepileptic drugs
2016-12-12 Despite the availability of generic antiepileptic drugs (AEDs), patients and neurologists still hesitate to make a switch due to several reasons. The objectives of this… Read More »
Biosimilars: management of clinical issues
2016-12-09 How to manage clinical issues encountered with biosimilars was a topic discussed in a review of biosimilars in rheumatology by author José M Serra López-Matencio… Read More »
Payers in US view biosimilars as a lower-cost branded option
2016-12-07 Payers in the US do not expect the biosimilars market to be like the generics market and they also do not expect the US biosimilars… Read More »
A multidisciplinary perspective on biosimilars
2016-12-05 A biosimilar is an officially regulated and approved copy of an originator biological therapy. Authors Khraishi et al. aimed to provide a comprehensive review of… Read More »